176 related articles for article (PubMed ID: 26282935)
1. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor expression correlates with serum CA125 and represents a useful tool in prediction of refractoriness to platinum-based chemotherapy and ascites formation in epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Oncotarget; 2015 Sep; 6(29):28491-501. PubMed ID: 26143638
[TBL] [Abstract][Full Text] [Related]
5. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Wang L; Mao Y; Du G; He C; Han S
Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer.
Zhang J; Tang L; Chen Y; Duan Z; Xiao L; Li W; Liu X; Shen L
Hum Pathol; 2015 Sep; 46(9):1331-40. PubMed ID: 26193797
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of ascites in epithelial ovarian cancer.
Huang H; Li YJ; Lan CY; Huang QD; Feng YL; Huang YW; Liu JH
Neoplasma; 2013; 60(5):546-52. PubMed ID: 23790174
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer.
Dobrzycka B; Mackowiak-Matejczyk B; Terlikowska KM; Kulesza-Bronczyk B; Kinalski M; Terlikowski SJ
Eur Cytokine Netw; 2013; 24(3):106-13. PubMed ID: 24197277
[TBL] [Abstract][Full Text] [Related]
10. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
[TBL] [Abstract][Full Text] [Related]
11. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
[TBL] [Abstract][Full Text] [Related]
13. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
14. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer.
Lu L; Katsaros D; Risch HA; Canuto EM; Biglia N; Yu H
Mol Carcinog; 2016 Apr; 55(4):357-65. PubMed ID: 25630839
[TBL] [Abstract][Full Text] [Related]
16. High expression of CDC6 is associated with accelerated cell proliferation and poor prognosis of epithelial ovarian cancer.
Deng Y; Jiang L; Wang Y; Xi Q; Zhong J; Liu J; Yang S; Liu R; Wang J; Huang M; Tang C; Su M
Pathol Res Pract; 2016 Apr; 212(4):239-46. PubMed ID: 26920249
[TBL] [Abstract][Full Text] [Related]
17. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer.
Ehlén A; Brennan DJ; Nodin B; O'Connor DP; Eberhard J; Alvarado-Kristensson M; Jeffrey IB; Manjer J; Brändstedt J; Uhlén M; Pontén F; Jirström K
J Transl Med; 2010 Aug; 8():78. PubMed ID: 20727170
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
19. Sprouty 2 protein, but not Sprouty 4, is an independent prognostic biomarker for human epithelial ovarian cancer.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
Int J Cancer; 2015 Aug; 137(3):560-70. PubMed ID: 25630587
[TBL] [Abstract][Full Text] [Related]
20. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
